Earlier this month (July 10, 2026), the German government voted through a sweeping set of provisions set to significantly impact medical cannabis patients who have their prescriptions covered by their statutory health insurance.
As the UK’s medical cannabis industry continues to come under fierce scrutiny from the country’s mainstream media, James Duckenfield, CEO of UK-based cannabis cultivator Glass Pharms, argues that the focus should be on ensuring compliance with the existing regulatory framework rather than sensationalising a prescribing rate that remains a small fraction of demonstrable clinical need.
The French medical cannabis market is now in the very final stage of decision-making before being implemented nationally, as the HAS presented its draft for the pricing and reimbursement strategy earlier this week.
Spain represents one of the most exciting incoming additions to the European medical cannabis market this year, as one of the continent’s largest producers finally moves toward domestic patient access after years of hard-fought advocacy.
Accredited Medical Cannabis Symposium Could ‘Benefit Thousands of Patients’, Says Expert
Curaleaf Laboratories has been confirmed as headline sponsor of the inaugural Cannabis Health Symposium, taking place on 25 November 2025 at Conway Hall, London.
Alternaleaf, a UK-based medical cannabis clinic, has launched the country’s first women’s health service dedicated to cannabis-based treatments for gynaecological and hormonal conditions.
UK clinic Releaf expands into Germany, leveraging its digital health ecosystem to capture market share in Europe’s fast-growing medical cannabis sector.
MOVES to boost medical cannabis access to UK patients are set to be discussed in parliament today.
